Mereo Biopharma Group Pl-adr (MREO) 13F Holders & Ownership Data (62 Funds, Q2 2026)

MREO ranks #5624 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

62 institutions disclose a position in MREO, but none treat it as a major bet — even Defilade Capital Management, L.P., its most concentrated holder, allocates just 0.3% of its own portfolio to it.

683 Capital Management, LLC has trimmed its MREO position for two straight quarters, cutting it by $2.5M while still holding $3.7M.

MREO is down 1.4% today, and institutions have been net sellers of $4.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MREO reported a net loss of $28.1M over the trailing twelve months.

• Not yet profitable — net loss of $28.1M over the trailing twelve months
• Revenue declined 0.0% year over year
• Net income improved year over year, from -$49.6M to -$28.1M
• Operating cash flow was negative, using $31.0M in cash
• Current ratio of 10.46x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range